BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 27449897)

  • 1. Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.
    Chaudhary M; Singh V; Anvikar AR; Sahi S
    Curr Comput Aided Drug Des; 2016; 12(4):282-293. PubMed ID: 27449897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling of human leucyl aminopeptidases for in silico off target binding analysis of potential Plasmodium falciparum leucine aminopeptidase (PfA-M17) specific inhibitors.
    Sahi S; Raj U; Chaudhary M; Nain V
    Recent Pat Endocr Metab Immune Drug Discov; 2014; 8(3):191-201. PubMed ID: 25269653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening.
    Ruggeri C; Drinkwater N; Sivaraman KK; Bamert RS; McGowan S; Paiardini A
    PLoS One; 2015; 10(9):e0138957. PubMed ID: 26406322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
    Drinkwater N; Vinh NB; Mistry SN; Bamert RS; Ruggeri C; Holleran JP; Loganathan S; Paiardini A; Charman SA; Powell AK; Avery VM; McGowan S; Scammells PJ
    Eur J Med Chem; 2016 Mar; 110():43-64. PubMed ID: 26807544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases.
    McGowan S; Oellig CA; Birru WA; Caradoc-Davies TT; Stack CM; Lowther J; Skinner-Adams T; Mucha A; Kafarski P; Grembecka J; Trenholme KR; Buckle AM; Gardiner DL; Dalton JP; Whisstock JC
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2449-54. PubMed ID: 20133789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
    González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
    Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of PfA-M1, over PfA-M17, by an amino-benzosuberone derivative blocks malaria parasites development in vitro and in vivo.
    Bounaadja L; Schmitt M; Albrecht S; Mouray E; Tarnus C; Florent I
    Malar J; 2017 Sep; 16(1):382. PubMed ID: 28934959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18.
    Paiardini A; Bamert RS; Kannan-Sivaraman K; Drinkwater N; Mistry SN; Scammells PJ; McGowan S
    PLoS One; 2015; 10(2):e0115859. PubMed ID: 25700165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and chemical validation of
    Edgar RCS; Siddiqui G; Hjerrild K; Malcolm TR; Vinh NB; Webb CT; Holmes C; MacRaild CA; Chernih HC; Suen WW; Counihan NA; Creek DJ; Scammells PJ; McGowan S; de Koning-Ward TF
    Elife; 2022 Sep; 11():. PubMed ID: 36097817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. X-ray crystal structures of an orally available aminopeptidase inhibitor, Tosedostat, bound to anti-malarial drug targets PfA-M1 and PfA-M17.
    Drinkwater N; Bamert RS; Sivaraman KK; Paiardini A; McGowan S
    Proteins; 2015 Apr; 83(4):789-95. PubMed ID: 25645579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and cellular characterisation of the Plasmodium falciparum M1 alanyl aminopeptidase (PfM1AAP) and M17 leucyl aminopeptidase (PfM17LAP).
    Mathew R; Wunderlich J; Thivierge K; Cwiklinski K; Dumont C; Tilley L; Rohrbach P; Dalton JP
    Sci Rep; 2021 Feb; 11(1):2854. PubMed ID: 33536500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of first-in-class plasmodium OTU inhibitors with potent anti-malarial activity.
    Siyah P; Akgol S; Durdagi S; Kocabas F
    Biochem J; 2021 Sep; 478(18):3445-3466. PubMed ID: 34486667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1'-region optimisation.
    Calic PPS; Vinh NB; Webb CT; Malcolm TR; Ngo A; Lowes K; Drinkwater N; McGowan S; Scammells PJ
    Eur J Med Chem; 2023 Feb; 248():115051. PubMed ID: 36634455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
    Cunningham E; Drag M; Kafarski P; Bell A
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3221-8. PubMed ID: 18458130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico screening of novel inhibitors of M17 Leucine Amino Peptidase (LAP) of Plasmodium vivax as therapeutic candidate.
    Rout S; Mahapatra RK
    Biomed Pharmacother; 2016 Aug; 82():192-201. PubMed ID: 27470355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.
    Skinner-Adams TS; Lowther J; Teuscher F; Stack CM; Grembecka J; Mucha A; Kafarski P; Trenholme KR; Dalton JP; Gardiner DL
    J Med Chem; 2007 Nov; 50(24):6024-31. PubMed ID: 17960925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
    Vinh NB; Drinkwater N; Malcolm TR; Kassiou M; Lucantoni L; Grin PM; Butler GS; Duffy S; Overall CM; Avery VM; Scammells PJ; McGowan S
    J Med Chem; 2019 Jan; 62(2):622-640. PubMed ID: 30537832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum.
    Kumari M; Chandra S; Tiwari N; Subbarao N
    BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.
    Mistry SN; Drinkwater N; Ruggeri C; Sivaraman KK; Loganathan S; Fletcher S; Drag M; Paiardini A; Avery VM; Scammells PJ; McGowan S
    J Med Chem; 2014 Nov; 57(21):9168-83. PubMed ID: 25299353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of leucyl aminopeptidase in Plasmodium falciparum parasites. Target for the antimalarial activity of bestatin.
    Gardiner DL; Trenholme KR; Skinner-Adams TS; Stack CM; Dalton JP
    J Biol Chem; 2006 Jan; 281(3):1741-5. PubMed ID: 16286469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.